CVRx, Inc.
NASDAQ:CVRXMedical - Devices
+$0.11 today
- Market cap
- $69.79M
- Beta
- 0.77
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.30M
CVRX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
CVRx, Inc.NASDAQ: CVRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $205K rose 11.4% year over year, behind the +15.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 10.8% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.
Context
- Depreciation & amortization amounted to 1.3% of revenue in FY2025, up 0.1 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.4% toward the trailing-twelve-month pace of +15.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 756K USD
- Year-over-year change
- +22.1%
- 4-year CAGR
- +45.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 756K | +22.1% |
| FY2024 | 2024-12-31 | 619K | +18.6% |
| FY2023 | 2023-12-31 | 522K | +26.7% |
| FY2022 | 2022-12-31 | 412K | +145.2% |
| FY2021 | 2021-12-31 | 168K | — |
Depreciation & Amortization vs competitors
How CVRX compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.6% is the 4th highest of 10, against a peer median of +3.1%.
- Depreciation & amortization amounts to 1.3% of revenue for CVRX, versus a peer median of 7.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.62M USD | +15.3% | +22.3% | 10.3% | |
| LTM Mar 2026 | $22.58M USD | +148.0% | +52.4% | 15.6% | |
| LTM Dec 2025 | $11.7M USD | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $4.31M USD | -7.1% | +33.4% | 7.5% | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| LTM Mar 2026 | $2M USD | +30.3% | -14.7% | 0.9% | |
| LTM Mar 2026 | $1.48M USD | +102.1% | -54.8% | 3.6% | |
| LTM Mar 2026 | $777K USD | +15.6% | +22.4% | 1.3% | |
| LTM Mar 2026 | $690K USD | +3.1% | -11.8% | 0.9% | |
| LTM Mar 2026 | $103K USD | -90.0% | +10.5% | 0.2% | |
| Peer median (excluding CVRX) | — | +3.1% | +1.0% | 7.5% | |
Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.08M) | (41.43M) | (41.2M) | (59.97M) | (53.31M) |
| Depreciation & Amortization | 168K | 412K | 522K | 619K | 756K |
| Deferred Income Tax | 14.62M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.91M | 3.89M | 6.3M | 19.05M | 11.05M |
| Change in Working Capital | (1.58M) | (5.57M) | (4.81M) | 949K | 1M |
| Accounts Receivables | (1.28M) | (2.94M) | (2.05M) | (1.72M) | (1.4M) |
| Inventory | (537K) | (3.08M) | (4.03M) | (1.12M) | (98K) |
| Accounts Payables | 27K | 1.21M | 165K | 698K | 1.25M |
| Other Working Capital | 207K | (761K) | 1.1M | 3.09M | 1.25M |
| Other Non-Cash Items | 229K | 25K | 158K | 203K | 327K |
| Operating Cash Flow | (27.73M) | (42.68M) | (39.02M) | (39.14M) | (40.17M) |
| Capital Expenditures | (1.18M) | (685K) | (591K) | (1.36M) | (580K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (1.18M) | (685K) | (591K) | (1.36M) | (580K) |
| Debt Repayment | (21.3M) | 7.5M | 22.5M | 20M | 0 |
| Common Stock Issued | 133.16M | 771K | 1.66M | 32.52M | 10.52M |
| Common Stock Repurchased | (1K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 23K | (7K) | 1.48M | 3.35M | 0 |
| Financing Cash Flow | 111.88M | 7.49M | 23.98M | 55.87M | 10.52M |
| Effect of Forex Changes | (8K) | (9K) | 3K | (1K) | 5K |
| Net Change in Cash | 82.96M | (35.88M) | (15.63M) | 15.36M | (30.23M) |
| Free Cash Flow | (28.92M) | (43.36M) | (39.61M) | (40.51M) | (40.75M) |
CVRx, Inc.
NASDAQ:CVRX
Intrinsic Alpha fair value
Locked
Current Price
$2.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.